Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors

CDMOs already play a critical role in the cell and gene therapy development and manufacturing space, says Rose Biosolutions. Emerging bioprocessing technologies, production methods, and strategies are creating even more opportunities for contractors.

Published by
GEN — Genetic Engineering & Biotechnology News
Evidence type
Laboratory

CDMOs already play a critical role in the cell and gene therapy development and manufacturing space, says Rose Biosolutions. Emerging bioprocessing technologies, production methods, and strategies are creating even more opportunities for contractors.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at GEN — Genetic Engineering & Biotechnology News.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Decentralization, AI, and Gene Editing Are Opportunities for CGT Contractors | Brilliant Blue Biosciences